2022

1. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

   Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953